Key Takeaways:
– Absci Corp. is partnering with Memorial Sloan Kettering Center to develop six novel cancer therapeutics with generative AI.
– Absci plans to design antibodies that bind to the cancer targets identified by MSK.
– The collaboration is a testament to the growing trend of using AI for drug discovery and development.
– This is Absci’s first partnership with a non-profit research organization.
– Founded by Sean McClain, Absci has been public since its 2021 IPO.
Seattle, WA – Absci Corp., a Vancouver, Washington-based organization specialized in the use of artificial intelligence (AI) for drug development, recently announced its collaboration with renowned cancer research center Memorial Sloan Kettering (MSK) based in New York. The partnership’s main goal is to create up to six innovative cancer therapeutics using generative AI. Both organizations aim to combine their respective areas of expertise in this milestone project.
AI Meets Oncology
MSK will utilize its immense oncology expertise to identify cancer targets. Subsequently, Absci will utilize AI technology to design antibodies that can bind effectively to the identified targets. This strategic collaboration is groundbreaking, reflecting how the integration of AI and life sciences is revolutionizing the arena of drug discovery and development. The news was first announced on Monday by ZDNet, crediting the J.P. Morgan Healthcare conference held this January in San Francisco for bringing the two organizations together.
A Rising Trend in Life Sciences
More life sciences companies and researchers have been turning to AI to facilitate drug discovery and development. As a result, the Pacific Northwest is promptly emerging as a leading hub for this burgeoning field. The expertise in AI and the life sciences sector sets this region apart, paving the way for some groundbreaking advancements.
Absci’s Unique Collaborations
Absci is not new to the world of collaborations. It already has existing partnerships with industry giants such as AstraZeneca, Merck, and NVIDIA. However, this new venture with MSK, a non-profit research institute, marks a first in Absci’s history. This milestone not only expands its collaborative network but also underscores the company’s commitment to advancing AI application in drug development.
The Absci Story
Absci was founded in 2011 by molecular and cellular biologist Sean McClain when he was only 22 years old. Since McClain’s innovative enterprise’s IPO in 2021, Absci has been publicly traded on Nasdaq. The collaborations and projects that Absci has undertaken reflect not only technological progress but also its potential for significant contributions to global health.
As AI meets oncology in this exciting new project, the fight against cancer achieves another level of potency. This partnership between Absci and MSK sets an example for future collaborations in the field of AI-driven drug development.
 for drug development, recently announced its collaboration with renowned cancer research center Memorial Sloan Kettering (MSK) based in New York.){kind=link}